Drug updated on 7/25/2024
Dosage Form | Ophthalmic solution (topical; 100% perfluorohexyloctane) |
Drug Class | Semifluorinated alkanes |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Perfluorohexyloctane (Miebo) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
- The information is derived from a systematic review and meta-analysis, which analyzed six randomized controlled trials (RCTs).
- Compared to control interventions, perfluorohexyloctane showed significant improvements in eye dryness score, ocular surface disease index, lipid layer thickness, and total corneal fluorescein staining.
- Fewer ocular treatment-emergent adverse events were reported with perfluorohexyloctane compared to controls; however, it was slightly less effective in improving tear film break-up time.
- High patient satisfaction was noted with perfluorohexyloctane tear substitutes according to the systematic review.
- No specific population types or subgroup considerations were provided; the study appears to have adopted a general population of DED patients.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Miebo (perfluorohexyloctane) Prescribing Information. | 2023 | Bausch & Lomb Americas Inc., Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Perfluorohexyloctane in dry eye disease: a systematic review of its efficacy and safety as a novel therapeutic agent. | 2023 | The Ocular Surface |